参附注射液联合丹参酮ⅡA 磺酸钠注射液治疗慢性阻塞性肺疾病急性加重期

摘要

Objective To observe the clinical efficacy of Shenfu Injection combined with Sulfotanshinone Sodium Injection in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease .Methods The 150 cases pa-tients were randomly divided into treatment group and control group ,respectively in 75 cases .All patients were given com-bined therapy such as oxygen treatment ,anti-infection ,bronchodilator ,glucocorticoid and nutritional foundation treatment , etc .On the basic of which ,the treatment group was given extra Shenfu Injection and Sulfotanshinone Sodium Injection intra-venously ,one time a day ,14 days in total .Observed the clinical effect ,lung function ,arterial blood and qi analysis index , hemorheology ,and BODE factors ,main symptoms changes before and after treatment .Results The efficacy rate of the treat-ment group was 88 .00% ,and that of the control group was 73 .33% .Compared with control group ,the treatment group could significantly improve VC ,FEV1/Pre% and FEV1/FVC% ( P<0 .05 ) ,decrease PaCO2 and hemorheology related fac-tors including blood viscosity ,erythrocyte sedimentation rate and so on ,also improve PaO2 and Body factors ( P<0 .05 ) .Ef-fectively improve the BODE index factor ( P<0 .05 ) ,as well as improving the patients' symptoms .Conclusion The combi-nation of Shenfu Injection and Sulfotanshinone Sodium Injection through correct abnormal hemorheology of patients ,improve the microcirculation ,improve PaO2 and decrease PaCO2 ,improve the BODE index factor to improve patients' life quality .%目的：观察参附注射液联合丹参酮ⅡA磺酸钠注射液治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法150例患者随机分为2组，治疗组和对照组各75例。2组患者均予控制性氧疗、抗感染、支气管扩张剂、糖皮质激素、营养支持等基础治疗。治疗组在上述治疗基础上加用参附注射液、丹参酮ⅡA磺酸钠注射液静脉滴注，1次／d ，共14 d。观察2组患者治疗前后临床疗效、肺功能、动脉血气分析指标、血液流变学及BODE指数、主要症状等相关因素的改善情况。结果治疗组与对照组有效率分别为88.00％和73.33％。治疗组在一定程度上有效增加了肺活量（VC ）、1秒钟用力呼气容积与预计值比值（FEV1／Pre％）和1秒钟用力呼气容积与用力肺活量比值（FEV1／FVC％）（ P＜0.05），降低二氧化碳分压（PaCO2），提高氧分压（PaO2）（ P＜0.05），有效降低全血低切黏度、全血高切黏度、红细胞沉降率等血液流变学指标（ P＜0.05），有效改善BODE指数各因子（ P＜0.05），并显著改善了患者临床症状。结论参附注射液联合丹参酮ⅡA磺酸钠注射液通过纠正患者血液流变学异常，改善微循环，增加PaO2，降低PaCO2缓解症状，降低BODE指数，改善预后，提高患者生存质量。